Blood Test for CTE: What 2026 Studies Show for Living Patients
Two peer-reviewed studies published in JAMA in November 2026 suggest that a blood test for CTE may help identify chronic traumatic encephalopathy (CTE) in living people. Right now, doctors can only confirm CTE by examining brain tissue after death, leading many former athletes, military veterans, and families to assume a routine lab draw is already available at a doctor’s office. In reality, the blood test remains an investigational research tool that primarily flags advanced stages of CTE rather than early symptoms, and it is not approved for clinical diagnosis.
Two November 2026 JAMA studies led by Boston University/Banner Health and Washington University in St. Louis found that elevated blood levels of a tau protein fragment called eMTBR-tau (or eMTBR-tau243) correlate with autopsy-confirmed CTE. The findings apply mainly to advanced-stage CTE in small research cohorts and are not yet validated or FDA-approved for individual patient testing. Former athletes and veterans experiencing memory or mood symptoms can still pursue thorough clinical evaluations today to rule out treatable conditions.

Is There a Blood Test for CTE in Living Patients Right Now?
Not for routine medical care yet, though two studies published in JAMA in November 2026 showed promising progress. Researchers at Boston University and Washington University in St. Louis found that elevated blood levels of a specific tau protein fragment accurately identified advanced-stage CTE pathology in small human study groups, pending larger validation trials and regulatory review.
Historically, CTE could only be diagnosed post-mortem. According to National Institute of Neurological Disorders and Stroke (NINDS) consensus criteria, a definitive diagnosis requires examining brain tissue under a microscope to see abnormal phosphorylated tau proteins clustered around small blood vessels at the depths of brain folds (cortical sulci). Because living patients cannot undergo brain tissue biopsies for this condition, clinicians have had to rely on symptom history and exclusion of other illnesses.
As detailed in the Boston University Chobanian & Avedisian School of Medicine announcement, the newly identified blood biomarker is still in the discovery phase. You cannot order a CTE blood test at Quest, LabCorp, or a primary care clinic today, and the authors emphasize that larger autopsy and clinical validation studies are needed before the test can guide personal medical decisions.
What the Two November 2026 JAMA Studies Actually Show
Much of the confusion in news headlines comes from two separate JAMA papers being reported side by side. Both investigated fragments from the microtubule-binding region of tau (eMTBR-tau), a protein that forms abnormal tangles inside injured brain cells, but they examined different patient cohorts.
| Study Feature | Boston University & Banner Health Study | Washington University in St. Louis Study |
| Publication date | Published November 19, 2026 in JAMA (PubMed abstract) | Published November 13, 2026 in JAMA (PubMed abstract) |
| Biomarker measured | Plasma eMTBR-tau | Cerebrospinal fluid and plasma eMTBR-tau243 |
| People studied | 21 former American football players who donated their brains | Cohorts with mixed tauopathies, including autopsy-confirmed CTE |
| Main finding | Higher blood eMTBR-tau levels associated with advanced CTE tau pathology | Elevated eMTBR-tau243 distinguished advanced CTE from non-CTE controls |
| Primary limitation | Small sample size of mostly male football donors; requires larger cohorts | Limited CTE case count; focused primarily on late-stage pathology |
A key challenge in CTE biomarker research is separating CTE from Alzheimer’s disease, since both conditions involve abnormal tau buildup. In both studies, researchers addressed this overlap by looking at another blood marker called p-tau217. While p-tau217 rises sharply in Alzheimer’s disease, it generally remains low in people with isolated CTE. Combining a high eMTBR-tau reading with a negative Alzheimer’s biomarker profile helps researchers isolate CTE-specific pathology.
Why the Test Detects Advanced CTE—Not Early Stages
A major detail left out of many brief news summaries is that these blood biomarkers reliably detected advanced (high-stage) CTE rather than early disease.
In neuropathology, CTE is typically graded from Stage I (mild, localized tau deposits) to Stage IV (widespread tau tangles and brain tissue shrinkage). In the November 2026 studies, blood levels of eMTBR-tau rose significantly in donors with advanced CTE pathology, whereas low-stage CTE released too little of the protein fragment into the bloodstream to separate reliably from people without CTE.
For readers, this distinction carries two practical takeaways:
- Who the findings apply to: The current evidence applies primarily to older individuals with heavy, cumulative head-impact exposure and advanced neurodegenerative pathology.
- Who the findings do not apply to: A future blood test based on these markers would not rule out early-stage brain changes in a 25- or 35-year-old athlete or veteran experiencing mild mood or attention difficulties.
Acute Concussion Blood Tests vs. Chronic CTE Blood Tests
Many people assume a CTE blood test already exists because emergency rooms in the United States use FDA-cleared blood tests for head injuries. Those hospital tests measure completely different brain proteins and answer a different medical question.
| Feature | FDA-Cleared Acute TBI Blood Tests | Experimental CTE Blood Test |
| Examples | Abbott i-STAT TBI; Banyan Brain Trauma Indicator | Investigational plasma eMTBR-tau / eMTBR-tau243 assays |
| Proteins measured | GFAP and UCH-L1 | eMTBR-tau fragments (paired with p-tau217) |
| When it is used | Within 12 to 24 hours after an acute blow to the head | Years after repetitive head impacts end |
| Clinical purpose | Helps ER doctors decide whether a head CT scan is needed to check for acute brain bleeding | Investigated to detect chronic tau tangle pathology during life |
| Availability | FDA-cleared for hospital and clinical lab use | Research-only; not FDA-cleared |
According to the FDA review summary for the i-STAT TBI test, acute TBI blood tests check for sudden cellular injury right after a concussion or fall. They cannot detect delayed, long-term tau accumulation associated with CTE.
What Doctors Can Evaluate Today If You Have Symptoms
Waiting years for an FDA-approved CTE blood test does not mean former athletes, military veterans, or families have to ignore concerning symptoms. As noted in the CDC Traumatic Brain Injury and Concussion symptom guide, difficulties with memory, concentration, irritability, depression, headaches, and sleep overlap heavily with common, treatable health conditions.
When clinicians evaluate living patients with a history of repetitive head impacts, they often use research frameworks such as Traumatic Encephalopathy Syndrome (TES) alongside a thorough workup to identify reversible causes. A practical evaluation generally involves four steps:
- See a specialist in brain injury or behavioral neurology: Ask your primary care doctor for a referral to a behavioral neurologist or a multidisciplinary concussion clinic. Military veterans can request an evaluation through the Veterans Health Administration Polytrauma/TBI System of Care.
- Complete formal neuropsychological testing: A neuropsychologist administers standardized pen-and-paper and digital tests to measure memory, attention, processing speed, and executive function, creating an objective baseline.
- Rule out structural and metabolic look-alikes: Doctors typically order a standard brain MRI to check for strokes, tumors, or other structural issues, alongside routine blood tests for thyroid function, vitamin B12 levels, and hormone imbalances.
- Screen for sleep disorders and mood conditions: Untreated obstructive sleep apnea, chronic pain, major depression, and post-traumatic stress disorder (PTSD) frequently cause severe brain fog and irritability after sports or military careers—and all respond to targeted medical treatment.
Questions to ask at your appointment:
- Which of my current symptoms could be caused by treatable conditions like sleep apnea, depression, or medication side effects?
- Would a formal neuropsychological baseline test help track my memory and focus over the next year?
- Are there observational brain-health studies or clinical registries for former athletes or veterans that I qualify to join?
Seek urgent medical care right away if anyone with a history of head trauma develops sudden weakness or numbness, slurred speech, seizures, severe worsening headaches, or acute thoughts of self-harm.
Frequently Asked Questions
Can a blood test diagnose CTE while you are alive?
Currently, CTE can only be confirmed after death through a neuropathological exam of brain tissue. Two November 2026 JAMA studies found that an investigational blood biomarker called eMTBR-tau correlates with advanced CTE pathology during life, but larger clinical trials are required before doctors can use it for diagnosis.
When will the CTE blood test be available to the public?
There is no confirmed public release date. Because the November 2026 studies involved small discovery cohorts, researchers must validate the test across larger, more diverse populations and obtain U.S. Food and Drug Administration (FDA) clearance before commercial laboratories or clinics can offer it.
Can you develop CTE without ever having a diagnosed concussion?
Yes. Research cited by the National Institute of Neurological Disorders and Stroke indicates that CTE is most strongly associated with cumulative, repetitive head impacts over years—including routine sub-concussive hits in contact sports or military blast exposure—rather than a single diagnosed concussion.
How do researchers tell CTE apart from Alzheimer’s disease in blood?
Both CTE and Alzheimer’s disease involve abnormal tau protein accumulation, which can elevate eMTBR-tau levels. Researchers distinguish the two by measuring a second marker called p-tau217, which rises significantly in Alzheimer’s disease but typically remains low in people who have CTE without Alzheimer’s.
Are there any blood tests for concussions that are FDA-approved right now?
Yes, the FDA has cleared emergency-room blood tests—such as the Abbott i-STAT TBI and Banyan Brain Trauma Indicator—that measure GFAP and UCH-L1 proteins within 12 to 24 hours of a head injury. Those tests help clinicians decide whether a patient needs a CT scan to check for acute brain bleeding, not chronic CTE.